Hello, I am Yoko Maeda, Director of Health Promotion Clinic.
Regarding “peptide therapy,” which has been drawing increasing inquiries at our clinic, major news is shaking the medical industry from the United States. In April 2026, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a push to ease restrictions on 14 previously restricted peptides, including BPC-157, to make them more accessible to patients.
Today, I would like to share the behind-the-scenes realities of the medical industry regarding this news, along with crucial points you must know for safe peptide therapy.
The Dangers of the “Gray Market” Created by Regulations
In 2023, citing safety and quality concerns, the U.S. FDA placed 19 peptides on its Category 2 Bulk Drug Substances list, essentially barring compounding pharmacies from producing them.
However, the demand from patients seeking health and recovery never faded. Consequently, this gave rise to a dangerous “gray market” of products sold online under the label “research use only” to evade regulatory oversight. The absence of oversight means unknown product quality, potential contamination, and the possibility of severe side effects like infections and hormone disruption.
If They Are So Effective, Why Not Seek FDA Approval?
This raises a common question: “If they are so excellent and in high demand, why not just make them fully approved FDA drugs?”
Here lies a major structural hurdle: the “patent wall.” Peptides are often superior to conventional small-molecule drugs because they can be delivered more precisely and efficiently, with fewer side effects. However, since many peptides (like BPC-157) exist naturally in the body, they are difficult to patent. Because they cannot be patented, major pharmaceutical companies are not incentivized to fund the extensive and costly clinical trials required for FDA approval. This is the primary reason why these highly effective molecules struggle to become formal, FDA-approved drugs.
The Significance of Deregulation and “503A Compounding Pharmacies”
The policy shift Secretary Kennedy is currently pushing aims to return these peptides to Category 1. This would allow licensed 503A compounding pharmacies—which operate under state oversight and produce sterile, regulated products—to manufacture them safely based on a physician’s prescription.
This is a tremendous step forward, helping to bring peptides out of the shadows so they can be used by doctors in a safe, structured, and evidence-driven manner.
Self-Diagnosis is Dangerous! The Risk of Masking Underlying Conditions
Finally, as a doctor, I must emphasize one critical warning: Please absolutely avoid “self-treating” with peptides obtained through online retailers.
Why? Because even if a peptide is relatively safe, it can mask an underlying condition that remains undiagnosed and untreated.
Conclusion: Safe Peptide Therapy Requires Medical Supervision
Peptides hold extraordinary potential to repair our bodies at the cellular level, but they are not a universal magic cure. There must be a structured, individualized treatment plan for safe and effective outcomes. Making comprehensive judgments—verifying where the peptides are sourced, determining optimal dosing, and checking for hidden underlying diseases—is absolutely essential.
At our clinic, your peptides will be sourced from licensed pharmacies and prescribed by a qualified clinician who understands their indications, dosing, and potential risks. If you are struggling with lingering health issues, slow injury recovery, or are interested in healthy aging, please consult with us before relying on unverified information online.